Astellas tweaked its plans for Tuesday, the day a trial was set to start over an alleged scheme to delay generics of immune-suppressant drug Prograf. Instead of heading to court, the Japanese pharma agreed to settle a handful of lawsuits, it announced.
The world of gene therapy--in which single-dose treatments correct debilitating defects--enjoyed something of a renaissance in 2014. Strong clinical results from leaders in the once-maligned field spurred renewed optimism, helping a new generation of startups secure millions in venture financing to develop their next-generation approaches to the field.
In the coming year, you can expect to see a lot more work being done on Asian deals, particularly for China. Through the course of this past year there have been growing signs of this global evolution.
Astellas has capped a string of new drug development deals by upping the ante on its pact with South San Francisco-based Cytokinetics. After handing over a $40 million upfront fee for their original 2013 deal, Astellas has come back with $75 million more in near-term financing and more than $600 million in milestones on the table.
After ringing up a key U.S. approval in September to threaten Johnson & Johnson's Zytiga, Astellas' Xtandi now has what it needs to ramp up its market-share battle in the EU, too.
Johnson & Johnson is walking away from a potential rheumatoid arthritis treatment from Astellas, nixing a deal that could have paid out at $945 million and putting the drug's stateside future in jeopardy.
Astellas and CoMentis are calling it quits on their partnership in Alzheimer's disease, as the Japanese drugmaker walks away from a deal valued at up to $760 million.
Japan's Astellas Pharma is the latest big drugmaker allured by the promise of gene therapy, mounting an R&D effort that could lead to a new treatment for an inherited eye disease.
Astellas and Medivation bagged that new Xtandi approval in prostate cancer. What next? Gear up for a head-to-head with Johnson & Johnson's Zytiga. And to do that, Medivation is expanding its sales force by 50%, Medical Marketing & Media reports
Japanese drugmaker Astellas Pharma has teamed up with Cancer Research U.K. to join forces on early-stage oncology R&D, working to identify new treatments for pancreatic cancer.